PT  - JOURNAL ARTICLE
AU  - Guler, Sabina A.
AU  - Müller, Ilena
AU  - Mancinetti, Marco
AU  - Bridevaux, Pierre-Olivier
AU  - Brutsche, Marin
AU  - Clarenbach, Christian
AU  - Garzoni, Christian
AU  - Lenoir, Alexandra
AU  - Naccini, Bruno
AU  - Ott, Sebastian R.
AU  - Piquilloud, Lise
AU  - Prella, Maura
AU  - Que, Yok-Ai
AU  - Soccal, Paola
AU  - Von Garner, Christophe
AU  - Geiser, Thomas
AU  - Funke-Chambour, Manuela
TI  - Impact of COVID-19 on Clinical Frailty Scale – a multicentre prospective cohort study
AID  - 10.1183/13993003.congress-2021.OA84
DP  - 2021 Sep 05
TA  - European Respiratory Journal
PG  - OA84
VI  - 58
IP  - suppl 65
4099  - http://erj.ersjournals.com/content/58/suppl_65/OA84.short
4100  - http://erj.ersjournals.com/content/58/suppl_65/OA84.full
SO  - Eur Respir J2021 Sep 05; 58
AB  - Background: The Clinical Frailty Scale (CFS) predicts short-term mortality in COVID-19, but the effect of COVID-19 on medium-term frailty is unknown.Objective: To estimate the impact of COVID-19 and factors associated with CFS at follow-up.Methods: Patients estimated their CFS before and 4 months after COVID-19. CFS ranges from 1-9 (very fit to terminally ill). The associations of 4-month post COVID-19 CFS with forced vital capacity (FVC), diffusion capacity for carbon monoxide (DLCO), 6-minute walk distance (6MWD), and dyspnea (modified Medical Research Council [mMRC]) were evaluated.Results: 132 survivors of COVID-19 (65% men) were included. Mean±SD age was 57±13 years. Change in CFS pre- to 4-month post-COVID-19 differed depending on the need for and kind of hospitalisation (Figure ). At follow-up 60 participants (45%) were vulnerable (CFS ≥3) and 9 (7%) frail (CFS ≥5). CFS correlated with FVC% (r=-0.36, p<0.0001), DLCO% (r=-0.33, p=0.0002), 6MWD (r=-0.39, p<0.0001), and mMRC (r=0.57, p<0.0001). These correlations remained significant in separate multivariable models adjusting for the confounders age, sex, mode of hospitalisation, and BMI, with the strongest association for mMRC (coefficient 0.09, p<0.0001, R2 0.42).Conclusions: COVID-19 accelerates frailty, particularly in patients with ICU hospitalisation. Dyspnea is the strongest determinant of 4-month post-COVID-19 frailty and should be addressed thoroughly.FootnotesCite this article as: European Respiratory Journal 2021; 58: Suppl. 65, OA84.This abstract was presented at the 2021 ERS International Congress, in session “Prediction of exacerbations in patients with COPD”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).